NCT06754540View on ClinicalTrials.gov

Azacitidine Combined with Donor Lymphocyte Infusion for Acute Myeloid Leukemia Post-transplant Relapse Prevention.

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 16, 2025

Primary Completion Date

January 1, 2027

Study Completion Date

January 1, 2027

Conditions

Acute Myeloid Leukemia (AML)Relapse

Interventions

DRUG

Azacitidine (AZA)

Azacitidine 32mg/m2

All Listed Sponsors

lead

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

OTHER

NCT06754540 - Azacitidine Combined with Donor Lymphocyte Infusion for Acute Myeloid Leukemia Post-transplant Relapse Prevention. | Biotech Hunter | Biotech Hunter